Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717844 · ClinicalTrials.gov registry record
Registry for Adults With Plasma Cell Disorders (PCD's)
A clinical trial of Multiple Myeloma and Amyloidosis, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT03717844 is a study of Multiple Myeloma and Amyloidosis that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 2,000 participants, above the 542-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (269% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03717844, a study of Multiple Myeloma and Amyloidosis, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).
Conditions Studied
Study Locations (1)
North Carolina
- North Carolina Cancer Hospital - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2029-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717844
The ClinicalTrials.gov registry entry for NCT03717844 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 542-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (269% higher). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT03717844 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03717844 about?
NCT03717844 is a clinical study titled "Registry for Adults With Plasma Cell Disorders (PCD's)". The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include...
What is the current status of trial NCT03717844?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2018-02-09. Estimated completion is 2029-02.
What conditions does trial NCT03717844 study?
This clinical trial studies the following conditions: Multiple Myeloma, Amyloidosis, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Light Chain Deposition Disease.
Who is sponsoring clinical trial NCT03717844?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03717844 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.